Evercore ISI Group Upgrades Bionomics to Outperform, Announces $6 Price Target
Evercore ISI Group analyst Joshua Schimmer upgrades Bionomics (NASDAQ:BNOX) from In-Line to Outperform and announces $6 price target.
HC Wainwright & Co. Maintains Neutral on Bionomics
HC Wainwright & Co. analyst Joseph Pantginis maintains Bionomics (NASDAQ:BNOX) with a Neutral.
Loop Capital Maintains Buy on Bionomics, Raises Price Target to $17
Loop Capital analyst Esther Hong maintains Bionomics (NASDAQ:BNOX) with a Buy and raises the price target from $10 to $17.
Reported Late Wednesday March 08, Bionomics Reports Promising Full Results Analysis From PREVAIL Phase 2 Study Of BNC210 Social Anxiety Disorder; PREVAIL Did Not Meet Its Primary Endpoint
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge
Results achieved statistical significance in post-hoc analysis of the full
Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Kimball International, Inc. (NASDAQ: KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock moved upwards by 63.5% to $0.28 during Wednesday’s regular session. The current volume…
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close at $114.92 on Friday.
Evercore ISI Group Downgrades Bionomics to In-Line, Lowers Price Target to $6
Evercore ISI Group analyst Joshua Schimmer downgrades Bionomics (NASDAQ:BNOX) from Outperform to In-Line and lowers the price target from $17 to $6.
All Focus Shifts To Bionomics’ PTSD Study After Anxiety Trial Disappoints
Bionomics Limited (NASDAQ:BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety…
Bionomics’ Social Anxiety Disorder Study Fails To Meet Primary Endpoint
Bionomics Limited (NASDAQ:BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD). …